What was the recent clinical milestone announced by Nyrada Inc (ASX:NYR)?

Nyrada Inc has officially activated its first clinical trial site at Nepean Hospital in New South Wales for the PROTECT-MI Phase IIa study.

What specific medical condition does Nyrada’s Xolatryp aim to treat?

Xolatryp targets ischemia-reperfusion injury, which is the tissue damage caused when blood flow is restored to the heart after a blockage or heart attack.

How does the PROTECT-MI Phase IIa trial impact the Nyrada (ASX:NYR) investment thesis?

This news shifts Nyrada from a pre-clinical narrative into a "clinical-stage" reality, which typically reduces some R&D execution risk for investors.

What is the mechanism of action for Nyrada’s lead drug candidate?

Xolatryp works by inhibiting Transient Receptor Potential Canonical (TRPC) ion channels. This novel biochemical approach is intended to block the pathways that lead to cellular damage during a cardiac event.

Why is the selection of Nepean Hospital significant for Nyrada (ASX:NYR)?

Nepean Hospital serves as the lead facility, meaning it is the first site capable of screening and enrolling eligible patients who have suffered a myocardial infarction.

What are the primary risks for investors following the PROTECT-MI trial launch?

The primary risk is "clinical failure," where the drug may prove safe but fail to show statistically significant efficacy in reducing heart damage compared to a placebo.

How does Nyrada (ASX:NYR) compare to other biotech companies in the cardiovascular space?

Nyrada is pursuing a "first-in-class" therapy, meaning it is attempting to fill a treatment gap where no other approved drugs currently exist.

Nyrada activates first site for Phase 2a trial

Written by Liezl GambePublished Apr. 22 2026Last Updated Apr. 22 2026

Nyrada (ASX:NYR) announced the activation of its first clinical trial site for the PROTECT-MI Phase 2a study.

Nepean Hospital in New South Wales, Australia, has been selected as the lead facility to begin recruitment for this critical research phase.

The activation signifies a formal transition into clinical operations, following the completion of site governance, intensive staff training, and the logistical delivery of the trial medication.

Eligible patients presenting at Nepean Hospital following a myocardial infarction (heart attack) can now be screened and enrolled in the study.

The PROTECT-MI trial is designed to evaluate the safety and preliminary efficacy of Nyrada’s lead drug candidate, Xolatryp.

The treatment focuses on reducing myocardial injury—specifically damage caused by ischemia-reperfusion—which occurs when blood flow is restored to heart tissue after a blockage.

Despite being a primary driver of long-term heart failure and mortality, there are currently no approved therapies that directly target this specific type of injury.

Xolatryp works by inhibiting transient receptor potential canonical ion channels, a novel approach intended to mitigate the secondary damage that often follows a cardiac event.

At the time of reporting, Nyrada’s share price was $0.60.